Peripheral Artery Disease (PAD)

ATTAIN-PAD is a clinical research study from Eli Lilly and Company. This study will test how
well and safely the investigational medicine can help participants with peripheral artery disease
(PAD) increase their walking distance compared to placebo.

Get Your Patient FormDownload Brochure
804-250-9859
Get Your Patient Form
Summary
ATTAIN-PAD is a clinical research study from Eli Lilly and Company. This study will test how well and safely the investigational medicine can help participants with peripheral artery disease (PAD) increase their walking distance compared to placebo.
Age
18 years and over
Qualifications
  • Have a BMI of 23 or higher
  • Have a diagnosis and symptoms of peripheral artery disease
  • Can walk without stopping for more than 150 meters or 492 feet for at least 3 months before the start of the study
  • Have not taken glucagon-like peptide-1 (GLP-1) treatments in the 2 months before the start of the study

Meet Our Team

Our experienced team will guide you through the process

Meet the Team

Dr. Call, co-founder of Clinical Research Partners, serves as President. He is a Certified Principle Investigator

Robert S. Call, MD, CPI

President

Annette Bennett, co-founder of Clinical Research Partners, serves as Chief Executive Officer and Research Director. She

Annette Bennett

Chief Executive Officer

Bo Vaughan is a native of Richmond, VA and forward-thinking health care strategist with a

Bo Vaughan, MD, MSHA, CPI

Medical Director

Mimi Franzen Canada

Chief Operations Officer

Jeanette Weller

EVP of Contracts and Budgets

Caitlin Vining

Controller CCRP

Kelly Craighead, BS, RN, CCRC

Regulatory Affairs Director

Carly McLaughlin, PharmD

Director of Pharmacy PharmD

Lisa Smith, BSN, RN

Director of Quality Assurance

Joy Walker

Director of Business Development

Aundraya Bray, LCSW

Clinical Operations Coordinator

Shawn Mease, CCRC, NRP, CCEMT-P

Director of Study Start-Up